Absolute Neutrophil Count in the Peripheral Blood Predicts Prognosis in Lung Cancer Patients Treated with Anlotinib

• Published in: Cancer management and research Vol. 13; pp. 3619 - 3627
• Main Authors: Chen, Rong, Lu, Fang-Ying, Liu, Bing, Huang, Jingwen, Zhou, Min, Dai, Ranran, Guo, Yi
• Format: Journal Article
• Language: English
• Published: New Zealand Dove Medical Press Limited 01.01.2021; Taylor & Francis Ltd; Dove; Dove Medical Press
• Subjects: absolute neutrophil count; anlotinib; Biomarkers; Blood; Cancer patients; Cancer therapies; Chemotherapy; Comparative analysis; Development and progression; Drug dosages; Growth factors; Health aspects; Kinases; Lung cancer; Lymphocytes; Medical prognosis; Medical records; Medical research; Medicine, Experimental; Metastasis; Mutation; Neutrophils; Original Research; overall survival; Patients; Prognosis; progression free survival; Regression analysis; Tumors; Tyrosine; lung cancer; overall survival; anlotinib; absolute neutrophil count; progression-free survival

Anlotinib is a multi-targeted tyrosine kinase inhibitor that inhibits tumor angiogenesis and cell proliferation. It is widely used as a third-line therapy for lung cancer. However, reliable prognostic biomarkers for predicting the efficacy of anlotinib are lacking. We conducted a retrospective study...